Chapin Davis Inc. Buys 459 Shares of Pfizer Inc. (NYSE:PFE)

Chapin Davis Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,258 shares of the biopharmaceutical company’s stock after purchasing an additional 459 shares during the quarter. Chapin Davis Inc.’s holdings in Pfizer were worth $1,617,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Oak Asset Management LLC boosted its holdings in shares of Pfizer by 39.1% in the 1st quarter. Oak Asset Management LLC now owns 24,215 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 6,809 shares in the last quarter. Roberts Wealth Advisors LLC bought a new position in Pfizer in the first quarter valued at about $1,374,000. Barry Investment Advisors LLC raised its stake in Pfizer by 1.1% during the first quarter. Barry Investment Advisors LLC now owns 192,573 shares of the biopharmaceutical company’s stock worth $5,344,000 after acquiring an additional 2,123 shares in the last quarter. SteelPeak Wealth LLC raised its stake in Pfizer by 62.6% during the first quarter. SteelPeak Wealth LLC now owns 38,810 shares of the biopharmaceutical company’s stock worth $1,077,000 after acquiring an additional 14,947 shares in the last quarter. Finally, Breakwater Capital Group boosted its stake in shares of Pfizer by 2.6% in the 1st quarter. Breakwater Capital Group now owns 46,276 shares of the biopharmaceutical company’s stock valued at $1,284,000 after purchasing an additional 1,163 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1 %

Shares of NYSE:PFE opened at $28.02 on Monday. The stock’s 50-day moving average is $27.90 and its 200 day moving average is $27.69. The company has a market cap of $158.78 billion, a PE ratio of -466.26, a P/E/G ratio of 1.10 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The business’s revenue was down 19.5% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date is Thursday, July 25th. Pfizer’s payout ratio is currently -2,799.53%.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, June 26th. Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.